February 22, 2023 03:18 PM EST
Pharma

J&J to im­pose new lim­its on 340B ac­cess af­ter in­dus­try court win

Paul Schloesser

Associate Editor

One phar­ma gi­ant is im­ple­ment­ing some ma­jor re­stric­tions on ac­cess to 340B drugs, which go in­to ef­fect next month.

John­son & John­son

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times